Dacarbazine is a type of medicine called an anticancer drug. It's used to treat certain types of skin cancer, like melanoma. It works by stopping the growth of cancer cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Dacarbazine for Hodgkin Lymphoma?
Dacarbazine is an intravenous chemotherapy drug, sometimes called DTIC, used for two cancers: melanoma that has spread beyond the skin to other parts of the body, and Hodgkin lymphoma, a cancer of infection-fighting white blood cells. In the US it is sold as a generic; the original brand, DTIC-Dome, is no longer marketed. In Hodgkin lymphoma, dacarbazine is almost always one part of a combination. It is the D in ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), which was the standard first treatment for about three decades and is still used, particularly for early-stage disease. For advanced disease, newer combinations keep dacarbazine but replace bleomycin with nivolumab, an immunotherapy drug, or brentuximab vedotin, an antibody that delivers chemotherapy to lymphoma cells. For melanoma, dacarbazine was long the standard drug, but its role is now limited. It shrinks tumors in roughly 10 to 20 percent of people, and it has not been shown to help people live longer. Immunotherapy drugs (such as ipilimumab) and targeted pills for melanomas with a BRAF gene change (such as vemurafenib) did better than dacarbazine in head-to-head trials, so dacarbazine is usually considered after those options or when they are not suitable.
Cancer cells divide often, and each division requires copying their DNA. Dacarbazine interferes with that process, slowing or stopping the growth of cancer cells. Its exact mechanism is not fully understood. The leading explanations are that it acts as an alkylating agent, attaching chemical groups to DNA so it cannot be copied properly, and that it blocks the building of new DNA. Because it targets dividing cells rather than cancer cells specifically, it also affects healthy tissues that renew quickly, especially the bone marrow, where blood cells are made. That is why blood counts are the main safety concern.
Dacarbazine is given only by vein, either as a short injection or an infusion over 15 to 30 minutes, by a nurse in a hospital or infusion clinic under a doctor experienced with chemotherapy. There is no pill or home form. The dose is calculated from body size and the schedule depends on the cancer. For melanoma, it is often given daily for 5 or 10 days in a row, repeated every 3 or 4 weeks. In Hodgkin lymphoma regimens such as ABVD, it is usually given on one day every two weeks alongside the other drugs. Before each cycle, blood tests check whether counts have recovered enough to go ahead; treatment may be delayed or the dose changed if they have not. Medicine to prevent nausea is typically given before each dose. Tell the nurse right away about any pain, burning or swelling at the IV site during the infusion, because dacarbazine can damage tissue if it leaks out of the vein.
Nausea, vomiting and loss of appetite are the most common effects, affecting more than 9 in 10 people during the first doses. Vomiting can last from 1 to 12 hours but usually settles after the first day or two of a cycle, and anti-nausea medicine helps. Some people get a flu-like illness with fever, muscle aches and tiredness lasting several days after larger doses. Hair thinning or loss, facial flushing or tingling, and rash can also occur. The most important serious effect is a drop in blood counts. Low white cells raise the risk of infection, and low platelets raise the risk of bleeding; in severe cases this can be life-threatening. Call the care team immediately for a fever, sore throat, ongoing cough or other signs of infection, or for unusual bleeding or bruising. Dacarbazine can rarely cause severe liver damage from clots in the liver's veins, mostly when combined with other chemotherapy. Yellowing of the skin or eyes, pain in the upper right belly, or sudden extreme tiredness should be reported to the care team immediately. Allergic reactions, including anaphylaxis, can occur. During an infusion, tell the nurse right away about hives, itching, or any trouble breathing or swallowing. After leaving the clinic, difficulty breathing or swallowing, or swelling of the face or throat, is an emergency: call 911. Hives or itching alone at home can be reported to the care team.
Dacarbazine caused birth defects and cancers in animal studies. It is generally not used during pregnancy unless the cancer team decides it is the best option, so anyone who is pregnant or could become pregnant should discuss this and contraception before starting. In animal studies, pregnancies fathered by treated males were also more often lost, so men whose partner could become pregnant should ask about contraception too. It is not known whether it passes into breast milk, so breastfeeding during treatment needs a decision with the care team. It is not given to people who have had an allergic reaction to it before. It can make skin more sensitive to sunlight, so protective clothing and sunscreen are sensible during treatment. No specific drug interactions are listed for dacarbazine, but other treatments that lower blood counts or strain the liver add to its risks, which is one reason the liver problem has been seen mostly with combination chemotherapy. Give the care team a full list of prescriptions, over-the-counter medicines and supplements, and check before starting anything new.
Treatment is planned in cycles, with rest weeks between them so the bone marrow can recover. Nausea tends to be worst on treatment days and fades within a day or two; tiredness and low blood counts tend to build over the cycle. Blood tests before each cycle, and regular scans, show how the body and the cancer are responding. In Hodgkin lymphoma, dacarbazine-containing regimens are given with the aim of cure, typically over several months, often with a scan partway through to decide whether to adjust treatment. In melanoma, the goal is usually to slow or shrink the cancer; because responses are uncommon, the team will check early whether it is working and switch if it is not. Hair and blood counts usually recover after treatment ends.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Dacarbazine, what you've noticed, or ask the community a question.